Helal Metwalli, Mohammad Najm Dadam, Gam Hong Pham, Minh Dung Nguyen, Omar Khalid Samir Abdelkader, Le Hoang Duc, Nguyen Minh Anh, Thanh Vuong Ngoc Thien, Ayatallah Farrag, Randa Elsheikh, Abdelrahman M Makram, Phillip Tran, Nguyen Tien Huy
{"title":"术前布地奈德对术后喉咙痛的影响:系统回顾和荟萃分析。","authors":"Helal Metwalli, Mohammad Najm Dadam, Gam Hong Pham, Minh Dung Nguyen, Omar Khalid Samir Abdelkader, Le Hoang Duc, Nguyen Minh Anh, Thanh Vuong Ngoc Thien, Ayatallah Farrag, Randa Elsheikh, Abdelrahman M Makram, Phillip Tran, Nguyen Tien Huy","doi":"10.1177/00185787251356137","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Postoperative sore throat (POST) is a common complication following endotracheal intubation. Various pharmacological interventions have been explored for POST prevention, with budesonide emerging as a promising option due to its anti-inflammatory properties. <b>Methods:</b> PubMed, Scopus, Web of Science and the Cochrane Library were searched following PRISMA guidelines. The primary outcomes were POST incidence and severity. Incidence data were pooled using random- or fixed-effects models. Severity analysis focused on budesonide versus saline studies, applying an ordinal logistic regression (mild, moderate, severe) with group assignment as the predictor, and predicted probabilities were computed in R. <b>Results:</b> Budesonide significantly reduced the incidence of POST compared to placebo (OR 0.28, 95% CI: 0.18-0.41, <i>P</i> < .001, <i>I</i> <sup>2</sup> = 52%) and no intervention (OR 0.09, 95% CI: 0.05-0.14, <i>P</i> < .001, <i>I</i> <sup>2</sup> = 0%). It demonstrated similar efficacy to magnesium sulfate and ketamine (<i>P</i> > .05). Budesonide also reduced POST severity, increasing the likelihood of mild symptoms while decreasing moderate and severe cases (OR 0.46, 95% CI: 0.26-0.81). Additionally, budesonide combined with dexamethasone was more effective than budesonide alone in reducing POST incidence and severity. <b>Conclusion:</b> Preoperative budesonide is an effective prophylactic agent for reducing the incidence and severity of POST. Its localized anti-inflammatory action, cost-effectiveness, and minimal systemic side effects make it a viable option for clinical use. However, variations in dosing and administration require further high quality RCTs to establish standardized guidelines.</p>","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787251356137"},"PeriodicalIF":0.7000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12405198/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effect of Preoperative Budesonide on Postoperative Sore Throat: A Systematic Review and Meta-Analysis.\",\"authors\":\"Helal Metwalli, Mohammad Najm Dadam, Gam Hong Pham, Minh Dung Nguyen, Omar Khalid Samir Abdelkader, Le Hoang Duc, Nguyen Minh Anh, Thanh Vuong Ngoc Thien, Ayatallah Farrag, Randa Elsheikh, Abdelrahman M Makram, Phillip Tran, Nguyen Tien Huy\",\"doi\":\"10.1177/00185787251356137\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> Postoperative sore throat (POST) is a common complication following endotracheal intubation. Various pharmacological interventions have been explored for POST prevention, with budesonide emerging as a promising option due to its anti-inflammatory properties. <b>Methods:</b> PubMed, Scopus, Web of Science and the Cochrane Library were searched following PRISMA guidelines. The primary outcomes were POST incidence and severity. Incidence data were pooled using random- or fixed-effects models. Severity analysis focused on budesonide versus saline studies, applying an ordinal logistic regression (mild, moderate, severe) with group assignment as the predictor, and predicted probabilities were computed in R. <b>Results:</b> Budesonide significantly reduced the incidence of POST compared to placebo (OR 0.28, 95% CI: 0.18-0.41, <i>P</i> < .001, <i>I</i> <sup>2</sup> = 52%) and no intervention (OR 0.09, 95% CI: 0.05-0.14, <i>P</i> < .001, <i>I</i> <sup>2</sup> = 0%). It demonstrated similar efficacy to magnesium sulfate and ketamine (<i>P</i> > .05). Budesonide also reduced POST severity, increasing the likelihood of mild symptoms while decreasing moderate and severe cases (OR 0.46, 95% CI: 0.26-0.81). Additionally, budesonide combined with dexamethasone was more effective than budesonide alone in reducing POST incidence and severity. <b>Conclusion:</b> Preoperative budesonide is an effective prophylactic agent for reducing the incidence and severity of POST. Its localized anti-inflammatory action, cost-effectiveness, and minimal systemic side effects make it a viable option for clinical use. However, variations in dosing and administration require further high quality RCTs to establish standardized guidelines.</p>\",\"PeriodicalId\":13002,\"journal\":{\"name\":\"Hospital Pharmacy\",\"volume\":\" \",\"pages\":\"00185787251356137\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12405198/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hospital Pharmacy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/00185787251356137\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hospital Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/00185787251356137","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
背景:术后喉咙痛是气管插管后常见的并发症。各种药物干预已被探索用于POST预防,布地奈德因其抗炎特性而成为一个有希望的选择。方法:按照PRISMA指南检索PubMed、Scopus、Web of Science和Cochrane Library。主要结局是POST的发生率和严重程度。发生率数据采用随机或固定效应模型汇总。严重程度分析集中于布地奈德与生理盐水研究,应用有序逻辑回归(轻度、中度、重度),以分组分配作为预测因子,并以r计算预测概率。结果:与安慰剂相比,布地奈德显著降低了POST的发生率(OR 0.28, 95% CI: 0.18-0.41, pi 2 = 52%)和无干预(OR 0.09, 95% CI: 0.05-0.14, pi 2 = 0%)。其疗效与硫酸镁、氯胺酮相近(P < 0.05)。布地奈德还降低了POST的严重程度,增加了轻度症状的可能性,同时减少了中度和重度病例(OR 0.46, 95% CI: 0.26-0.81)。此外,布地奈德联合地塞米松在降低POST发生率和严重程度方面比单独布地奈德更有效。结论:布地奈德是一种有效的预防药物,可降低术后并发症的发生率和严重程度。其局部抗炎作用、成本效益和最小的全身副作用使其成为临床使用的可行选择。然而,剂量和给药的差异需要进一步的高质量随机对照试验来建立标准化的指南。
Effect of Preoperative Budesonide on Postoperative Sore Throat: A Systematic Review and Meta-Analysis.
Background: Postoperative sore throat (POST) is a common complication following endotracheal intubation. Various pharmacological interventions have been explored for POST prevention, with budesonide emerging as a promising option due to its anti-inflammatory properties. Methods: PubMed, Scopus, Web of Science and the Cochrane Library were searched following PRISMA guidelines. The primary outcomes were POST incidence and severity. Incidence data were pooled using random- or fixed-effects models. Severity analysis focused on budesonide versus saline studies, applying an ordinal logistic regression (mild, moderate, severe) with group assignment as the predictor, and predicted probabilities were computed in R. Results: Budesonide significantly reduced the incidence of POST compared to placebo (OR 0.28, 95% CI: 0.18-0.41, P < .001, I2 = 52%) and no intervention (OR 0.09, 95% CI: 0.05-0.14, P < .001, I2 = 0%). It demonstrated similar efficacy to magnesium sulfate and ketamine (P > .05). Budesonide also reduced POST severity, increasing the likelihood of mild symptoms while decreasing moderate and severe cases (OR 0.46, 95% CI: 0.26-0.81). Additionally, budesonide combined with dexamethasone was more effective than budesonide alone in reducing POST incidence and severity. Conclusion: Preoperative budesonide is an effective prophylactic agent for reducing the incidence and severity of POST. Its localized anti-inflammatory action, cost-effectiveness, and minimal systemic side effects make it a viable option for clinical use. However, variations in dosing and administration require further high quality RCTs to establish standardized guidelines.
期刊介绍:
Hospital Pharmacy is a monthly peer-reviewed journal that is read by pharmacists and other providers practicing in the inpatient and outpatient setting within hospitals, long-term care facilities, home care, and other health-system settings The Hospital Pharmacy Assistant Editor, Michael R. Cohen, RPh, MS, DSc, FASHP, is author of a Medication Error Report Analysis and founder of The Institute for Safe Medication Practices (ISMP), a nonprofit organization that provides education about adverse drug events and their prevention.